Your browser doesn't support javascript.
loading
The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells.
Viñado, Ana C; Calvo, Isabel A; Cenzano, Itziar; Olaverri, Danel; Cocera, Miguel; San Martin-Uriz, Patxi; Romero, Juan P; Vilas-Zornoza, Amaia; Vera, Laura; Gomez-Cebrian, Nuria; Puchades-Carrasco, Leonor; Lisi-Vega, Livia E; Apaolaza, Iñigo; Valera, Pablo; Guruceaga, Elisabeth; Granero-Molto, Froilan; Ripalda-Cemborain, Purificacion; Luck, Tamara J; Bullinger, Lars; Planes, Francisco J; Rifon, José J; Méndez-Ferrer, Simón; Yusuf, Rushdia Z; Pardo-Saganta, Ana; Prosper, Felipe; Saez, Borja.
Afiliação
  • Viñado AC; Hematology-Oncology Program, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.
  • Calvo IA; Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain.
  • Cenzano I; Hematology-Oncology Program, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.
  • Olaverri D; Centro de Investigación Biomédica en Red de Cáncer, CIBERONC, Madrid, Spain.
  • Cocera M; Hematology-Oncology Program, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.
  • San Martin-Uriz P; Tecnun Universidad de Navarra, School of Engineering, 20018, San Sebastian, Spain.
  • Romero JP; Hematology-Oncology Program, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.
  • Vilas-Zornoza A; Hematology-Oncology Program, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.
  • Vera L; Hematology-Oncology Program, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.
  • Gomez-Cebrian N; Hematology-Oncology Program, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.
  • Puchades-Carrasco L; Regenerative Medicine Program, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.
  • Lisi-Vega LE; Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe, 46026, Valencia, Spain.
  • Apaolaza I; Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe, 46026, Valencia, Spain.
  • Valera P; Wellcome-MRC Cambridge Stem Cell Institute, Department of Hematology, University of Cambridge, and NHS Blood and Transplant, Cambridge, CB2 0AW, UK.
  • Guruceaga E; Tecnun Universidad de Navarra, School of Engineering, 20018, San Sebastian, Spain.
  • Granero-Molto F; Universidad de Navarra, Centro de Ingeniería Biomédica and DATAI Instituto de Ciencia de los Datos e Inteligencia Artificial, 31008, Pamplona, Spain.
  • Ripalda-Cemborain P; Hematology-Oncology Program, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.
  • Luck TJ; Hematology-Oncology Program, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.
  • Bullinger L; Regenerative Medicine Program, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.
  • Planes FJ; Cell Therapy Area, Clínica Universidad de Navarra, 31008, Pamplona, Spain.
  • Rifon JJ; Department of Orthopaedic Surgery and Traumatology, Clínica Universidad de Navarra, 31008, Pamplona, Spain.
  • Méndez-Ferrer S; Regenerative Medicine Program, CIMA Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008, Pamplona, Spain.
  • Yusuf RZ; Department of Orthopaedic Surgery and Traumatology, Clínica Universidad de Navarra, 31008, Pamplona, Spain.
  • Pardo-Saganta A; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany.
  • Prosper F; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Saez B; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Cancer Immunology, Berlin, Germany.
Leukemia ; 36(8): 1969-1979, 2022 08.
Article em En | MEDLINE | ID: mdl-35618797
ABSTRACT
Eradicating leukemia requires a deep understanding of the interaction between leukemic cells and their protective microenvironment. The CXCL12/CXCR4 axis has been postulated as a critical pathway dictating leukemia stem cell (LSC) chemoresistance in AML due to its role in controlling cellular egress from the marrow. Nevertheless, the cellular source of CXCL12 in the acute myeloid leukemia (AML) microenvironment and the mechanism by which CXCL12 exerts its protective role in vivo remain unresolved. Here, we show that CXCL12 produced by Prx1+ mesenchymal cells but not by mature osteolineage cells provide the necessary cues for the maintenance of LSCs in the marrow of an MLLAF9-induced AML model. Prx1+ cells promote survival of LSCs by modulating energy metabolism and the REDOX balance in LSCs. Deletion of Cxcl12 leads to the accumulation of reactive oxygen species and DNA damage in LSCs, impairing their ability to perpetuate leukemia in transplantation experiments, a defect that can be attenuated by antioxidant therapy. Importantly, our data suggest that this phenomenon appears to be conserved in human patients. Hence, we have identified Prx1+ mesenchymal cells as an integral part of the complex niche-AML metabolic intertwining, pointing towards CXCL12/CXCR4 as a target to eradicate parenchymal LSCs in AML.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medula Óssea / Leucemia Mieloide Aguda Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medula Óssea / Leucemia Mieloide Aguda Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha